This week, Promega Corporation announced the opening of the Kornberg Center, a new three-story 280,000-square-foot (over 85,000 square meters) research and development facility at its Fitchburg campus. Kornberg Center will support core product and technology development in life science research, cellular and molecular biology, genetic identity, clinical diagnostic and scientific applications, and training.
At Gilson, we help life scientists at the bench achieve more productive research and verifiable data. And during the pandemic, we’ve helped support critical testing workflows and other COVID-related initiatives.
by Thomas LynchVice President, Client Services, AldevronBoard Member, BioForward The team at Aldevron is excited to virtually celebrate our recent expansion in Madison and share the great progress we’re making and opportunities ahead in the world of gene therapy. Aldevron’s Protein Business Unit manufactures recombinant proteins used in a wide range of applications including research, […]
Read the full press release here Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based […]
Read the full press release here Small environmental and academic teaching laboratories specializing in water analysis can benefit from simpler setup and operation and improved quality with a new, compact ion chromatography (IC) system that can bring an advanced level of simplicity to anion and cation analyses of drinking water. The new Thermo Scientific Dionex […]
Read the full press release here LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, today announced plans to create a program to offer total antibody testing at no charge through the patient’s doctor in support of increased blood plasma donations for use as a possible COVID-19 treatment. LabCorp […]
Read the full press release here Throughout history, infectious diseases caused by pathogens have taken a devastating toll on the lives and security of people around the world. However, with the ongoing COVID-19 pandemic comes challenges that have never been faced before. The biopharmaceutical industry is committed to the discovery and the development of treatments […]
Read the full press release from Catalent here. Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19. Under the terms […]
Read the full press release from Illumina here. Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Illumina COVIDSeq™ Test, a high-throughput, sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2. […]
Read the full press release from Eurofins here. Eurofins Technologies announces the launch of a serology-based total antibody (IgG, IgA and IgM) detection ELISA assay for indirect diagnostic of past exposure to COVID-19. The development of the assay has been led by Eurofins Ingenasa, a Eurofins Technologies company involved in the development of diagnostic tests […]